Hyderabad, India and Gaithersburg, MD, USA — Ocimum Biosolutions, a leading integrated genomics solutions company, today announced that Prof. Joseph Paulauskis from the International Genomics Consortium has joined the company’s Scientific Advisory Board. This development strengthens Ocimum’s commitment to work with key thought leaders to build sustained expertise around its vision for serving as a unique ‘Research as a Service’ (RaaS) platform in Genomics for global Pharmaceutical and Biotech Organizations.
Prof. Paulauskis’ interests and expertise areas include Pharmacogenomics, Drug Safety and Translational Medicine. He is currently an Adjunct Associate Professor in the Department of Pathology at Michigan Medical School, Ann Arbor. He is also a manager at the International Genomics Consortium at Phoenix, Arizona.
He was involved with academic research at Harvard University for more than a decade besides a long leadership stint in research and development for Pfizer Inc. He also led management of external collaborations and representation of Pfizer to key opinion leaders, collaborating institutions, and regulatory agencies. Until joining the International Genomics Consortium (IGC), he led a multi-disciplinary group providing high quality Pharmacogenomic support across therapeutic areas for research and clinical trials including development of Lipitor, Lyrica, Detrol, Camptosar, Sutent, and Chantix. Ms. Anu Acharya, CEO, Ocimum Biosolutions says, “Prof. Paulauskis is an important thought leader in the field of Genomics. His presence in our Scientific Advisory Board will be pivotal as we continue to expand our solutions in key genomics knowledge sectors.”
“We look forward to closely working with him in our efforts for providing a global infrastructure for Research As a Service. There are exciting times ahead of us. We are delighted to have him on our Scientific Advisory Board.” Ms. Acharya added.
Prof. Paulauskis said “ I’m pleased and excited to once again be working with the talented colleagues at Ocimum–Genelogic. The ‘Research as a Service’ platform has real potential to fundamentally change the relationship between genomics vendor and the biotechnology and pharmaceutical industry”.
About Ocimum Biosolutions
Ocimum Biosolutions is a global integrated genomics services company with operations in Hyderabad, India and Gaithersburg, MD in the US. Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.
Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.
For more information, please visit www.ocimumbio.com
